Latest News and Press Releases

Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel...

Global leaders in science, medicine, and journalism join the Global Virus Network’s Board to strengthen pandemic preparedness and global health

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years1-3Transformational...

HAMBURG, Germany, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Mindpeak, a global pioneer in AI-powered pathology solutions, is today thrilled to announce that it has been granted its first patent, covering a...

Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS)...

Ottawa, Dec. 09, 2025 (GLOBE NEWSWIRE) -- According to Precedence Research, the global gRNA market size is expected to be worth over USD 3,171.65 million by 2034, increasing from USD 708.92 million...

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient...

Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median...

FOR IMMEDIATE RELEASE -- ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 -- Updated clinical data presented at ASH show robust efficacy,...

Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and...